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The effect of combinations of the mutagenic base analog 5-fluorouracil (FU) and the antiviral inhibitors
guanidine hydrochloride (G) and heparin (H) on the infectivity of foot-and-mouth disease virus (FMDV) in cell
culture has been investigated. Related FMDV clones differing up to 106-fold in relative fitness in BHK-21 cells
have been compared. Systematic extinction of intermediate fitness virus was attained with a combination of FU
and G but not with the mutagen or the inhibitor alone. Systematic extinction of high-fitness FMDV required
the combination of FU, G, and H. FMDV showing high relative fitness in BHK-21 cells but decreased
replicative ability in CHO cells behaved as a low-fitness virus with regard to extinction mutagenesis in CHO
cells. This confirms that relative fitness, rather than a specific genomic sequence, determines the FMDV
response to enhanced mutagenesis. Mutant spectrum analysis of several genomic regions from a preextinction
population showed a statistically significant increase in the number of mutations compared with virus pas-
saged in parallel in the absence of FU and inhibitors. Also, in a preextinction population the types of mutations
that can be attributed to the mutagenic action of FU were significantly more frequent than other mutation
types. The results suggest that combinations of mutagenic agents and antiviral inhibitors can effectively drive
high-fitness virus into extinction.
An increase in the mutation rate during replication of RNA
viruses can result in a decrease of viral infectivity and occa-
sional virus extinction (11, 34, 39, 40, 60). Studies with the
important animal pathogen foot-and-mouth disease virus
(FMDV)—a member of the Picornaviridae family (53, 63)—
have shown that a small replicative population size and low
viral fitness favored virus extinction (60). This was documented
with single and multiple passages of FMDVs differing up to
106-fold in relative fitness in the absence or presence of the
mutagenic base analogs 5-fluorourocil (FU) or 5-azacytidine,
individually or in combination (59, 60). Mutagenic treatments
resulted in occasional, not systematic, viral extinction, while
parallel passages in the absence of mutagens never led to loss
of infectivity, no matter how low the initial viral population size
and fitness were (59, 60). These results suggested the possibil-
ity that a combination of an antiviral inhibitor, to reduce the
replicative load of virus, and a mutagenic agent could be more
effective in producing viral extinction than a mutagenic agent
used in isolation. To test this possibility we have studied the
effect of the mutagenic base analog FU and the antiviral in-
hibitors guanidine hydrochloride (G) and heparin (H) on the
infectivity of FMDV clones and populations depicting a wide
range of relative fitness values. FU has been shown to be
mutagenic for a number of RNA viruses (6, 20, 31, 34, 51, 71),
including FMDV (59, 60). G at millimolar concentrations
blocks the replication of picornaviruses (5, 7, 15, 49, 52, 55),
arboviruses (27), and several plant viruses (13, 67). In poliovi-
rus, the target of G is the ATPase activity of nonstructural
protein 2C (49), a protein involved in viral replication and
encapsidation. In FMDV, amino acid substitutions at 2C have
also been associated with resistance to G (56). Heparins are
sulfated polysaccharides (9) which bind FMDV when the virus
has been passaged in cell culture and has adapted to using
heparan sulfate (HS) as a receptor (2, 35, 54). Adaptation to
use of HS as a receptor has been associated with substitutions
which lead to positively charged amino acids at exposed posi-
tions of the capsid (2, 54).
Here we report that high-frequency extinctions of FMDV of
low and intermediate fitness values can be achieved with a
combination of FU and G but not with either drug alone.
Extinction of high-fitness FMDV populations required a triple
combination of G and H together with FU. Mutation frequen-
cies in the mutant spectrum of three genomic regions of a
preextinction population obtained by the combined action of
an inhibitor and a mutagen were compared to values in ge-
nomes passaged in standard conditions and also to values pre-
viously determined for FMDV populations subjected to one or
multiple passages in the presence of FU (60). We found that
mutation frequencies increased up to fourfold. There was also
a statistically significant increase in the number of mutations in
preextinction populations with respect to control populations,
and the frequency of mutation types that can be attributed to
the mutagenic action of FU was significantly higher than the
frequency of other types of mutations.
MATERIALS AND METHODS
Cells and viruses. The origins of baby hamster kidney 21 cells (BHK-21) and
Chinese hamster ovary cells (CHO) have been previously described (3, 18, 25,
62). Both cell types were grown in Dulbecco’s modified Eagle’s medium
* Corresponding author. Mailing address: Centro de Biologı´a Mo-
lecular “Severo Ochoa,” Universidad Auto´noma de Madrid, Canto-
blanco, 28049 Madrid, Spain. Phone: 34-91-397 8485. Fax: 34-91-397
4799. E-mail: edomingo@cbm.uam.es.
† Present address: Institu¨t fu¨r Virologie, Universita¨t zu Ko¨ln, 50935
Ko¨ln, Germany.
9723
 at CTRO
 BIO
LO
G
IA M
O
L SEVERO
 O
CHO
A on Novem
ber 6, 2008 
jvi.asm.org
D
ow
nloaded from
 
(DMEM) (Gibco) supplemented with nonessential amino acids (Gibco), 50 mg
of gentamicin (Sigma)/ml, and 5% fetal calf serum (Gibco).
FMDV C-S8c1 is a plaque-purified derivative of the European serotype C
natural isolate C1 Santa Pau-Spain 70 (62). MARLS is a monoclonal antibody
escape mutant obtained from FMDV C-S8c1 passaged 213 times in BHK-21 cells
(C-S8c1p213) (3). MARLS includes the substitution L-1443S at antigenic site
A, located within the G-H loop of the capsid protein VP1 (43, 44). In BHK-21
cells, the replicative fitness of MARLS is about 130-fold higher than that of
C-S8c1 (59). In CHO cells the replicative fitness of MARLS is lower than in
BHK-21 cells, as indicated by a delayed kinetics of viral production and a 10-fold
reduction in the viral titer at the point of complete cytopathic effect. No ranking
of the relative fitnesses of FMDV mutants has been established with CHO cells.
Clones H955 1 to 5 are a series of low-fitness subclones from the clone H5
(derived from C-S8c1p113 [23]) after 95 plaque-to-plaque transfers in BHK-21
cells (C. Escarmı´s et al., unpublished results). Relative fitness of the H955 sub-
clones was estimated on the basis of the number of infectious progeny produced
per plaque (23): their relative fitness is about 104-fold lower than that of C-S8c1
virus. A good correspondence between relative fitness values obtained in growth
competition experiments and those estimated on the basis of infectious progeny
production has been previously documented with several FMDV clones and
populations (23); Escarmı´s et al., unpublished results).
Procedures for infection of BHK-21 cell monolayers with FMDV in liquid
medium and for plaque assays in semisolid agar medium have been previously
described (3, 18, 62). The standard viral production assay with BHK-21 cells
consisted of the infection of 9  105 cells with FMDV at a multiplicity of
infection of approximately 0.05 PFU per cell. Further passages were carried out
with 0.1 ml of the supernatant of the previous infection. For assays with CHO
cells, 9  105 cells were infected with FMDV MARLS at a multiplicity of
infection of 1 PFU per cell in the first passage, and the following passages were
carried out with 0.1 ml of the supernatant of the previous passage. Except for
preextinction populations, the multiplicity of infection of successive passages
ranged from 0.001 to 1 PFU per cell, and the value for each individual infection
can be calculated from the titers shown in the corresponding figures. To control
for the absence of viral contamination, parallel passages of supernatants of
mock-infected cells were carried out throughout the experiments, with no evi-
dence of infectivity or cytopathology in the cultures. Viruses were titrated at
every passage, on BHK-21 cell monolayers, in triplicate.
Mutagenic and antiviral treatments. To prepare culture medium containing
FU (Sigma), the appropriate amount of analog was dissolved in DMEM to yield
a 2.5-mg/ml solution, which was diluted in DMEM as needed for the experi-
ments. To prepare medium containing G (Sigma), the appropriate amount was
dissolved in DMEM to yield a 4 mM solution (0.38 mg/ml). To prepare medium
containing a mixture of both FU and G, the appropriate amount of G was added
to DMEM containing FU (200 g/ml) to yield FUG, a solution containing FU
(200 g/ml) and G (4 mM). H (Heparin sodium salt; Sigma) was dissolved in
water and diluted in DMEM or FUG (to yield FUGH, a solution containing FU
[200 g/ml], G [4 mM], and H [1 mg/ml]) as needed for the experiments. All
solutions were sterilized by filtration. Media were supplemented with 2% fetal
calf serum and stored at 4°C for a maximum of 14 days. The effect of FU,
inhibitors, or their combination on cell viability was monitored by trypan blue
exclusion as described previously (60). Before counting, cells were washed with
DMEM, detached by trypsin treatment, and resuspended in DMEM supple-
mented with 2% fetal calf serum. Viable BHK-21 cells comprised at least 20% of
the total (Fig. 1), under the doses and times of exposure used for the experi-
ments. CHO cells were more resistant than BHK-21 cells to the treatments, and
after exposure to FUG, approximately 80% of the cells were viable (N. Pariente
et al., unpublished data).
In order to establish whether the 20% of BHK-21 cells that were left after 37
h of exposure to FUGH were able to sustain FMDV replication, cell monolayers
that had been preincubated for 13 h with FU and for 24 h with FUGH were
washed with DMEM and incubated for 2 h with DMEM supplemented with 2%
fetal calf serum. Then, the cells were infected either with MARLS, at a multi-
plicity of infection of about 10 PFU per cell, or with the low-fitness H955 clone, at
about 0.005 PFU per cell. Parallel infections of confluent BHK-21 cell mono-
layers were carried out as a control. The titer of MARLS attained in treated cells
was 1  107 PFU/ml, versus 4  108 PFU/ml in untreated cells. In the case of the
low-fitness H955 clone, titers were 7  104 PFU/ml and 1  107 PFU/ml, respec-
tively. This implies that cytotoxicity cannot account for viral extinction, since
even a very low-fitness virus can carry out its life cycle in treated cells in
infections started with very low numbers of infectious units.
Viral infections in the presence of FU, inhibitors, or their combination. Dif-
ferent standard single infections were carried out in parallel. (i) In control
infections (absence of mutagen and inhibitors), confluent cell monolayers were
infected with FMDV (adsorption for 45 min at 37°C), washed for 1 min with 0.1
M phosphate buffer (pH 6.0) (to inactivate unadsorbed virions), and washed
again extensively with DMEM. The infection was allowed to proceed in DMEM
supplemented with 2% fetal calf serum. (ii) For infections in the presence of FU,
confluent cell monolayers were pretreated for 13 h with 200 g of FU/ml and
then washed with DMEM; the procedure was done as for the control infections,
and the infection was allowed to proceed in the presence of the same concen-
tration of FU. (iii) For infections in the presence of G, no pretreatment of the
cell monolayer was performed; after addition of FMDV and washing of the cell
monolayers, the infection was allowed to proceed in the presence of 4 mM G. (iv)
For infections in FUG, confluent cell monolayers were pretreated for 13 h with
200 g of FU/ml and then washed with DMEM. After virus adsorption and
washing of cell monolayers, the infection proceeded in the presence of FUG. (v)
For infections in H, no pretreatment of the cell monolayer was performed;
FMDVs were preincubated with 1 mg of H/ml for 30 min at room temperature.
After inoculation and washing of the cell monolayers, the infection was allowed
to proceed in the presence of 1 mg of H/ml. (vi) For infections in the presence
of FUGH, confluent cell monolayers were pretreated for 13 h with 200 g of
FU/ml and then washed with DMEM. Viruses were preincubated with 1 mg of
H/ml for 30 min at room temperature. After virus adsorption and washing of the
cell monolayers, the infection proceeded in the presence of FUGH. All infec-
tions were allowed to continue for approximately 24 h.
For serial passage of virus, 0.1 ml of cell culture supernatant from the previous
infection was used to infect a cell monolayer pretreated with a mutagen as
described above for the standard single infections. Virus was titrated after each
passage. When no cytopathology was observed, at least three serial blind pas-
sages using undiluted cell culture supernatant, in the absence of mutagen and
antiviral agents, were carried out prior to viral detection tests. Viral extinction is
defined on the basis of two criteria, as previously described (60): absence of
infectivity in the cell culture supernatant after the last blind passage and no
amplification of viral genomic regions by reverse transcription and PCR ampli-
fication. Populations passaged in the presence of a mutagen or antiviral agents
are indicated with the abbreviation of the culture medium used, followed by the
passage number (e.g., C-S8c1FUGp1 is C-S8c1 passaged once in the presence of
a mixture of FU and G).
cDNA synthesis, PCR amplification, and nucleotide sequencing. Viral RNA
was extracted as previously described (60) using 150 l of culture medium; for
preextinction populations (virus in the passage prior to extinction), the volume
used was 1 ml due to the low viral load present in these samples. cDNA synthesis
and PCR amplification (reverse transcription-PCR [RT-PCR]) were performed
FIG. 1. BHK-21 cell viability in the presence of FU, G, and H,
alone or in combination. The origin of BHK-21 cells and FMDV
C-S8c1, as well as procedures for cell growth, antiviral treatment,
quantification of cell viability, and infections with FMDV, are detailed
in Materials and Methods. Percent cell viabilities (trypan blue exclu-
sion) were calculated relative to those in parallel, untreated cell cul-
tures, counting 300 to 700 cells per sample. Hours of exposure refers
to the time elapsed between the addition of the mutagen or antiviral
agent to cells and the determination of cell viability. Standard devia-
tions (not included in the plots) never exceeded 20%.
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as previously described (23). In all cases cDNA synthesis was carried out using
avian myeloblastosis virus reverse transcriptase (Promega). Amplification was
performed with Taq polymerase (Perkin-Elmer) for determination of the con-
sensus sequences and for the extinction test. Amplifications intended for molec-
ular cloning and nucleotide sequencing of individual clones were carried out with
the Expand High Fidelity PCR System (Roche) (4). To ensure an excess of
template molecules for amplification, only the samples for which RT-PCR am-
plification of 1/10 of the initial RNA template was also positive were used for
molecular cloning of the cDNA. Three FMDV genomic regions were subjected
to RT-PCR amplification: residues 3193 to 3869 (spanning the VP1-coding
region), residues 4280 to 5349 (spanning the 2C-coding region), and residues
6609 to 8035 (spanning the entire 3D [polymerase]-coding region). Numbering of
FMDV genomic nucleotides is that used in reference 65. The oligonucleotide
primers used to amplify the VP1- and 3D-coding regions have been previously
described (60). The following primers were used for 2C amplification: 5-TCG
GAGCTCCGATTCTGTTGGCCGGGTTG-3, termed 2BR3SacI (sense, 5 po-
sition 4253), and 5-AAAGAATTCAATTGCTGCCTCGTGTTG-3, termed
3AD4EcoRI (antisense, 5 position 5376); they include restriction enzyme sites
for SacI and EcoRI, respectively (underlined). Amplified cDNAs coding for
VP1, 2C, and 3D were digested with the appropriate restriction enzymes, ligated
to plasmid pGEM-4Z (Promega) previously digested with the same restriction
enzymes, and cloned into Escherichia coli DH5 as described previously (60).
DNA from bacterial colonies was obtained by direct PCR amplification from
colony lysates using the commercial primers SP6 and T7 (Promega), which are
complementary to positions flanking the polylinker site of pGEM-4Z. Nucleotide
sequences were determined using the Big Dye Terminator Cycle Sequencing kit
(ABI Prism; Perkin-Elmer) and the automated sequencer ABI373. Each muta-
tion was confirmed by two independent sequencing assays using primers of
different orientation. Sequences were analyzed with the DNA Star 4.0, Genedoc,
and GCG package programs.
The heterogeneity of the mutant spectrum of viral quasispecies was quanti-
tated by use of the mutation frequency and normalized Shannon entropy (Sn)
(68). Mutation frequency is the number of different mutations found relative to
the number of nucleotides sequenced; it is calculated by dividing the number of
different mutations found in a set of genomes (compared to the consensus nu-
cleotide sequence of the same set) by the total number of nucleotides sequenced
(16, 21). Sn is a measure of the proportion of identical sequences in a mutant
distribution. The possible values of the Sn range from zero (when all genomes
are identical) to one (when all genomes differ from one another) (60, 68).
RESULTS
Systematic extinction of C-S8c1 by a combination of FU and
G. G at a concentration of 4 mM in the culture medium causes
a 10- to 102-fold reduction in the production of FMDV C-S8c1
with no significant effect on BHK-21 cell viability. The combi-
nation of 200 g of FU/ml and 4 mM G (FUG) resulted in a
decrease of cell viability to about 40% of that of the untreated
cells (Fig. 1). To test whether FUG was more effective than
either FU or G alone in inhibiting viral production, FMDV
MARLS, C-S8c1, and five low-fitness subclones derived from
H95
5 were used to infect BHK-21 cells in the absence or pres-
ence of FU, G, or FUG. The FMDVs used differed up to
106-fold in relative fitness value (see Materials and Methods).
The results (Fig. 2) show that FUG led to reductions in viral
production that were 102- to 103-fold larger than those ob-
served in the presence of FU or G alone. Yields of the sub-
clones H95
5 3, H95
5 4 and H95
5 5 in the presence of FU were
undetectable, but virus reemerged after one passage. However,
extinction of the subclones H95
5 1 to H95
5 5 was observed in
all cases in one passage in the presence of FUG.
Previous results showed that serial passage of FMDV
C-S8c1 in the presence of FU resulted in occasional, not sys-
tematic, extinction of the virus (60). To evaluate the frequency
of extinctions of C-S8c1 in the presence of FUG, serial pas-
sages were carried out as detailed in Materials and Methods.
Extinction of C-S8c1 was observed at passage 2 in the presence
of FUG but not in the presence of FU or G alone (Fig. 3). To
test the robustness of C-S8c1 extinction under these condi-
tions, 46 replicates of an infection of 3 105 BHK-21 cells with
104 PFU of C-S8c1 in the presence of FUG were analyzed. Ex-
tinction was observed in all cases at the second passage. Thus,
the combination of the mutagenic base analog FU and the
antiviral inhibitor G was much more effective than FU alone in
producing viral extinction. Systematic extinction was observed
with the standard reference FMDV C-S8c1 clone after two
passages and with low-fitness H95
5 clones after only one passage
in the presence of the mutagen-inhibitor combination.
Efficient extinction of MARLS in CHO cells. MARLS dis-
plays a 130-fold-greater fitness than C-S8c1 in BHK-21 cells
(59, 60), as a result of 213 serial passages in BHK-21 cells (3).
However, its fitness in CHO cells is at a much lower level, as
judged from a 10-fold-lower progeny production, than in BHK-
21 cells. Therefore, if difficulties for extinction of MARLS in
infections in the presence of FUG were due to its high fitness
(Fig. 2), MARLS should manifest an increased susceptibility to
FU and FUG in infections of CHO cells. The results (Fig. 4)
show that extinction of MARLS occurred after three passages
in CHO cells with FU and after two passages with FUG,
suggesting that resistance to extinction of MARLS in BHK-21
cells was due to its high fitness in the environment provided by
BHK-21 cells and not to an intrinsic property of the MARLS
genome to be refractory to extinction.
FIG. 2. Effect of viral fitness on the decrease of infectivity in a
single round of infection in the absence or presence of FU, G, or the
mixture of both (FUG). FMDV MARLS, C-S8c1, and H95
5 clones are
described in Materials and Methods. Empty columns indicate viral
production in the absence of mutagen or antiviral agent; gray columns
indicate viral production in the presence of 200 g of FU/ml; striped
gray columns indicate viral production in the presence of 4 mM G; and
black columns show viral production in the presence of FUG. In this
experiment 9  105 BHK-21 cells were infected with 5  104 PFU of
virus. Extinction of the five H95
5 FUGp1 clones was confirmed by three
additional blind passages, in the absence of mutagen and inhibitor with
no evidence of infectivity, and no RT-PCR-amplifiable material in the
supernatant of the third passage. Yields of H95
5 3, H95
5 4, and H95
5
5 clones in the presence of FU were undetectable (10 PFU/ml), but
virus reemerged after one blind passage in the absence of the mutagen.
However, these clones were extinguished upon a second passage in the
presence of FU. Titrations were done in triplicate, and standard devi-
ations are indicated. Procedures for chemical mutagenesis, antiviral
treatment, and determination of viral infectivity are described in Ma-
terials and Methods.
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High-fitness virus can be extinguished with the combination
of a mutagen and two inhibitors. The effect of FUG on FMDV
C-S8c1 suggested that extinction of high-fitness MARLS in
BHK-21 cells could be favored by decreases in the viral load
achieved with the combination of two antiviral inhibitors tar-
geted to different steps in the virus life cycle. To test this
possibility, the the effect of combination of FU, G, and H
(FUGH) on production of MARLS in BHK-21 cells was
tested. The FUGH treatment resulted in a decrease of cell
viability to about 20% of the untreated cells (Fig. 1). Control
experiments (described in Materials and Methods) ruled out
cytotoxicity as being responsible for the absence of viral pro-
duction. The results (Fig. 4) show that a combination of two
inhibitors and a mutagen can lead to extinction of MARLS in
BHK-21 cells in three passages. In order to elucidate how
systematic the extinctions were, 47 repetitions of the passages
in the presence of FUGH were performed. In 40 cases extinc-
tion of MARLS was obtained in the third passage and in 7
cases in the fourth passage. Therefore, a combination of a
mutagen and multiple inhibitors is effective in promoting sys-
tematic extinction of high-fitness FMDV.
Evidence for FU-induced mutations in a preextinction pop-
ulation and moderate increases in mutation frequency. Con-
sensus nucleotide sequences and sequences from molecular
clones were obtained from the mixture of the supernatants of
the 46 replicates of the C-S8c1FUGp1 preextinction popula-
tion and C-S8c1DMEMp1 (Fig. 3). Three genomic regions
were analyzed, the ones encoding the capsid protein VP1 and
the nonstructural proteins 2C and 3D. Increases in mutation
frequencies ranged between 1.5- and 4-fold; the maximum
difference was found in 3D (Table 1) as in a previous report
(60). The number of mutations observed in the C-S8c1FUGp1
population was significantly higher than that obtained with
C-S8c1DMEMp1, as measured with the 2 test (P  0.005 and
P 	 0.001; 2, 1 degree of freedom). The most abundant mu-
tations found in the preextinction populations were the tran-
sitions A3G and U3C (Table 2), which have been associated
FIG. 3. Serial passages of C-S8c1 in the absence or presence of FU,
G, or FUG. In this experiment, 9  105 BHK-21 cells were infected
with 5  104 PFU of FMDV C-S8c1, and subsequent infections were
carried out with 0.1 ml of supernatant of the previous passage (the
multiplicity of infection at each passage can be calculated from the
titers shown in ordinate). The origin of FMDV C-S8c1, conditions for
mutagenic and antiviral treatment, and those for determination of
FMDV infectivity are described in Materials and Methods. The pre-
extinction population is indicated by an arrow. Viral extinction was
confirmed by three additional blind passages in the absence of muta-
gen and inhibitor with no evidence of infectivity, and no RT-PCR-
amplifiable material was found in the supernatant of the third passage.
All titrations were done in triplicate. Standard deviations (not included
in the plots) never exceeded 15%.
FIG. 4. Infectivity values upon passage of FMDV MARLS in the absence or presence of FU, G, or FUG in BHK-21 and CHO cells. Conditions
for mutagenic and antiviral treatments and for determination of FMDV infectivity are detailed in Materials and Methods. Left panel: FMDV
MARLS was tested by infecting 9  105 BHK-21 cells with 5  104 PFU of virus, and the next passages were carried out by infecting cells with
0.1 ml of supernatant from the previous passage. Right panel: 9  105 CHO cells were infected with 9  105 PFU of FMDV MARLS, and passages
were carried out as for the infections of BHK-21 cells. The multiplicity of infection at each passage can be calculated from the titers shown in
ordinate. Preextinction populations are indicated by arrows. Viral extinction was ascertained by three additional blind passages in the absence of
mutagen and inhibitors, with no evidence of infectivity and RT-PCR-amplifiable material in the supernatant of the third passage. All titrations were
done in triplicate. Standard deviations (not included in the plots) never exceeded 15%.
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with the mutagenic action of FU (37, 59, 72). The number of
A3G and U3C transitions was found to be significantly
higher than other mutation types with the 2 test (P  0.025
and P 	 0.01; 2, 1 degree of freedom). Increases were found
in Shannon entropy, which is a measure of the different types
of nucleotide sequences found in the mutant spectrum of the
genomic region under study. Thus, in the three genomic re-
gions analyzed, the mutant spectrum of the population near
extinction was more complex than that in the corresponding
control population (Table 1).
DISCUSSION
The possibility of a new antiviral strategy based on increasing
the mutation rate above a threshold value (16, 34, 36, 40, 41)
stems from the quasispecies dynamics of RNA virus popula-
tions (21, 57, 64). Error rates during RNA genome replication
dictate that viral genomes consist of a complex mutant spec-
trum often dominated by a most fit genome, termed the master
sequence (21, 22). Error-prone replication predicts an error
threshold relationship of the form

max  ln 0/(1  q) (1)
in which vmax is the maximum length (information contents)
that can be stably maintained in a viral genome, 0 is the
selective advantage (superiority) of the master sequence over
the mutant spectrum, and q is the average copying fidelity (in
a scale from 0 to 1) during genome replication; therefore (1 
q) is the average error rate (21, 22, 57, 64). According to the
error threshold relationship, an increase in the error rate
above a threshold value should result in the loss of information
carried by the viral genome and therefore in a loss of infectiv-
ity. Experimental support for this theoretical prediction has
been obtained by subjecting vesicular stomatitis virus, poliovi-
rus (10, 11, 34, 39), and human immunodeficiency virus type 1
(40) to increased levels of mutagenesis. In the case of FMDV
we showed previously that low fitness and reduced viral loads
favored viral extinction upon replication in the presence of FU
or 5-azacytidine or their combination (59, 60). Relative fitness
among viral populations is conceptually parallel to relative
fitness among components of the mutant spectrum within a
viral population. The parameter 0 in equation 1 represents
the superiority of the master sequence over its mutant spec-
trum, and its value is larger the higher the relative fitness of the
mutant distribution (21, 22, 57). Therefore, virus extinction
should be favored in populations with low relative fitness, as
observed experimentally (59, 60).
Further evidence that low fitness rather than a specific
genomic structure was responsible for virus extinction has been
obtained with infection of CHO cells with MARLS. This virus
showed low fitness in CHO, as evidenced both by a 10-fold-
lower progeny production than in BHK-21 cells and a 10-fold
increase in progeny production after eight serial passages in
CHO cells (N. Pariente et al., unpublished results). MARLS
was prone to extinction with a combination of mutagen and
one inhibitor and with the mutagen alone in CHO cells but not
in BHK-21 cells (compare the graphics in Fig. 4). The viral
load also has a definite influence in the adaptation (fitness
increase) of viral quasispecies. When the viral population size
is small, genetic drift and a decrease in fitness prevail (8, 23, 73,
74), while when the replicative size of the same virus clones
and populations is large, competitive selection of increasingly
adapted mutant swarms leads to exponential increases in viral
fitness (24, 46, 47, 69).
These previous theoretical and experimental observations
suggested that a combination of a mutagenic agent and anti-
viral inhibitors should increase the frequency of viral extinc-
tions. This has indeed been documented in the present report
by using FMDV clones and populations differing by about 106-
fold in relative fitness values. For the reference virus C-S8c1,
whose relative fitness value is taken as 1 (23, 24), a combina-
tion of FU and G resulted in 47 extinction events out of 47
trials. For MARLS, which has a 130-fold-greater fitness than
TABLE 2. Types of mutations in the mutant spectrum of
FMDV C-S8c1 preextinction and control populationsa
Mutation typeb
No. of mutations in C-S8c1 population
DMEMp1 FUGp1
A3C 1 1
A3G 1 13
A3U 0 1
C3A 6 1
C3G 0 1
C3U 3 4
G3A 1 1
G3C 0 0
G3U 1 3
U3A 0 0
U3C 3 14
U3G 0 0
Total 16 39
a Populations, nucleotides analyzed, number of clones, and treatment condi-
tions are described in Materials and Methods, in footnotes a and c of Table 1,
and in the legend for Fig. 3.
b Mutations are those found in the analysis of the mutant spectra of the VP1-,
2C-, and 3D-coding regions of the indicated C-S8c1 populations.
TABLE 1. Genetic heterogeneity in the mutant spectrum of FMDV
C-S8c1 populations subjected to one passage in DMEM or in FUGa
C-S8c1
population
Encoded
proteinb
No. of
clonesc
No. of
nucleotidesd
Mutation
frequencye Sn
f
DMEMp1 VP1 25 16,075 5.0  104 (100) 0.38
2C 20 19,080 5.2  104 (80) 0.56
3D 20 28,080 1.1  104 (67) 0.20
FUGp1 VP1 20 12,860 9.3  104 (50) 0.54
2C 20 19,080 7.9  104 (67) 0.75
3D 19 26,676 4.5  104 (42) 0.53
a The populations analyzed and the antiviral treatments are described in Ma-
terials and Methods and in the legend for Fig. 3. C-S8c1FUGp1 is the preex-
tinction population indicated with an arrow in Fig. 3. C-S8c1DMEMp1 is the
population passaged in parallel in DMEM.
b VP1 is encoded at positions 3193 to 3869, 2C at 4280 to 5349, and 3D at 6609
to 8035 of the FMDV genome; numbering is as in reference (65).
c Number of cDNA clones in E. coli analyzed (the procedure is detailed in
Materials and Methods).
d Total number of nucleotides sequenced for each genomic region.
e Number of different mutations found divided by the number of nucleotides
sequenced (for each population and genomic region), expressed as substitutions
per nucleotide. Mutations were counted comparing the sequence of each indi-
vidual clone with the consensus sequence of the corresponding population. The
percentage of nonsynonymous mutations is indicated in parenthesis.
f The normalized Shannon entropy is calculated as i[(pi  ln pi)/ln N], in
which pi is the frequency of each sequence in the mutant spectrum and N is the
total number of sequences compared (60, 68).
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C-S8c1 in BHK-21 cells, two inhibitors were needed in com-
bination with FU, to obtain viral extinction. This extinction was
also obtained for each of 48 trials, in fewer than five passages.
We term this occurrence systematic extinction, since chances
of virus surviving for a larger number of passages under these
adverse evolutionary conditions must be negligible. Not unex-
pectedly, clones whose fitness was 103- to 104-fold-lower than
that of C-S8c1 did not survive even a single round of infection
under the same conditions.
The mutant spectrum of an FMDV C-S8c1 preextinction
population, subjected to passages in the presence of FUG, has
been compared with the mutant spectrum of a C-S8c1 popu-
lation passaged in DMEM. With the RT-PCR amplification
system used, the mutation frequency values found in the mu-
tant spectra analyzed cannot be affected by mutations intro-
duced during the amplification procedures (1, 4, 59, 60). There
was a significant bias toward the type of mutations induced by
FU expected from the ambiguous reading of fluorouridine in
template molecules (37, 59, 72). In the VP1-, 2C-and 3D-
coding regions, 50, 67, and 42%, respectively, of the mutations
were nonsynonymous (Table 1). The locations of amino acid
replacements in VP1, 2C, and 3D are given in Table 3. Two
amino acid replacements were found in the carboxy-terminal
region of VP1 (antigenic site C [43]) (Q1913H and H1973
R). In 2C, replacement R1093H affected the A domain, a
Walker nucleoside triphosphate binding motif (49). In 3D,
except for the T3653A change in  strand 4, which is a very
conserved position among picornavirus polymerases (75), all
other replacements were located on loops linking  helices and
 strands, assuming that structural elements of poliovirus 3D
(30) coincide with those of FMDV 3D upon alignment of the
two amino acid sequences (42).
One of the possible drawbacks of the combination therapy
presented herein would be the appearance of guanidine-resis-
tant FMDV mutants due to the action of FU. There have been
several guanidine-resistant mutants of poliovirus described,
and some of FMDV serotype O, and most of them involve
transition mutations presumably favored by FU (50, 56). Nev-
ertheless, none of the clones analyzed from a preextinction
FMDV population showed mutations described as responsi-
ble for a guanidine-resistant phenotype, despite the fact that
FMDV replication in the presence of G alone can result in
selection of resistant mutants (55, N. Pariente et al., unpub-
lished results). In case resistant mutants arose during treat-
ments with mutagen and inhibitors, there would be a compe-
tition between the selection of the inhibitor-resistant mutant
and the mutational force towards extinction. When such a
force dominates, chances of selecting resistant mutants dimin-
ish, and this may explain why no G-resistant mutants were
detected in the mutant spectra analyzed. The option of using
two inhibitors that act on different steps of the viral life cycle
reduces the possibility of the mutagen generating escape mu-
tants. The FMDV-FUG or -FUGH combination system pro-
vides a simple cell culture model system for studying the dy-
namics of mutational pressure in relation to G-resistant or H-
resistant mutant generation and efficiency of extinction. These
studies are currently in progress.
The need of combination therapy with two or more inhibi-
tors to limit the chances of generating and selecting inhibitor-
resistant mutants in viral quasispecies has been emphasized
(17, 19, 29, 33). Early experiments suggested a more effective
control of influenza virus by a combined vaccine-antiviral strat-
egy (32, 45, 70). In a conceptually parallel study, ribavirin (1-
-D-ribofuranosyl-1H-1,2,4-triazole-3-carboxamide) treatment
prevented the appearance of neutralization-resistant mutants
of lymphocytic choriomeningitis virus in mice (58). Recent
reports (10, 11) have documented that ribavirin can be muta-
genic for poliovirus and that in this system reduction of infec-
tious virus production correlated with mutagenic activity of the
nucleotide analog. These results were interpreted as suggesting
that the antipoliovirus activity of ribavirin could be due to the
transition of viral replication into error catastrophe (10, 11),
although viral extinction was not observed. Ribavirin is used in
the therapy of a number of viral infections (12, 14, 48, 61).
Certainly the contribution of inhibition versus mutagenesis in
the antiviral action of ribavirin deserves further investigation.
Also, the possible contribution of inhibition of virus-specific
RNA synthesis in the extinction by FU—suggested by the re-
duction in viral production in a single round of infection in the
presence of FU (59, 60)—requires further investigation. Our
observations on the benefits of a combination of a mutagenic
agent and one or several antiviral inhibitors are consistent with
current views on adaptability of viral quasispecies (8, 16, 21–24,
26, 46, 47, 69). The lesser the opportunity of a virus to repli-
cate, the lower the chances of survival in the face of an antiviral
response, be it natural (an immune response) or induced ex-
ternally (through immune stimulation, immunotherapy, or drug
administrations).
TABLE 3. Amino acid replacements found in VP1, 2C, and 3D of
the mutant spectrum of preextinction population C-S8c1FUGp1
Protein Amino acidreplacementa Structural or functional element
b
VP1 P1113Q l
F1593S H
I1693V I
Q1913H l
H1973R l
2C D563G N-terminus, amphipathic domain
I853V Unknown
R1093H Between the 2C loop and the A domain
S1123P A domain
T1353A Unknown
D1463G Unknown
T2133A Unknown
R2263G Unknown
I2483T Unknown
K3173T C-terminus, RNA binding domain
3D V1433A l
Q2323H l
I2903T l
T3653A 4
I4523V l
a The single-letter amino acid code is used; amino acids are numbered inde-
pendently for each protein, as in (references 23, 24, 43, 44, 59, and 65).
b Structural elements (,  strand; 1, loop) of VP1 are assigned according to
the three-dimensional structure of FMDV C-S8c1 (38); structural elements of
3D are based on the three-dimensional structure of poliovirus 3D (30), assuming
that the equivalent positions of FMDV in an alignment of the two sequences (42)
belong to the same structure. The assignment of functional domains of 2C are
based on those described for poliovirus in references 28, and 49 and references
therein; sequence identity was based in an alignment between 2C of poliovirus
(66) and FMDV C-S8c1 (65) (N. Pariente, unpublished results).
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